KIAA0247 Inhibits Growth, Migration, Invasion of Non-small-cell Lung Cancer Through Regulating the Notch Pathway

Overview

Journal Cancer Sci

Specialty Oncology

Date 2018 Feb 17

PMID 29451718

Citations 15

Authors

Yitong Xu

Hongjiu Ren

Jun Jiang

Qiongzi Wang

Muli Wudu

Qingfu Zhang

Hongbo Su

Chenglong Wang

Lihong Jiang

Xueshan Qiu

Affiliations

Soon will be listed here.

Abstract

Lung cancer remains the leading cause of cancer-related death worldwide. Previous studies have shown that the novel KIAA0247 gene potentially targeted by the tumor suppressor p53 may inhibit the development of several cancers. However, the exact function of KIAA0247 in non-small-cell lung cancer (NSCLC) is unknown. The purpose of the present study was to clarify the role of KIAA0247 in NSCLC. KIAA0247 expression was evaluated in tumors and adjacent normal tissues of 197 NSCLC patients by immunohistochemistry and real-time PCR and analyzed for association with clinicopathological parameters. Results indicated that KIAA0247 levels positively correlated with cell differentiation (P < .001) and patient survival (P < .0001) and negatively correlated with lymph node metastasis (P < .001) and advanced p-TNM stage (P < .001). In cultured NSCLC cell lines, KIAA0247 overexpression inhibited cell migration, invasion, and proliferation and downregulated the expression of Jagged1, Notch1 intracellular domain (NICD), Snail, cyclin D1, RhoA, RhoC, and MMP9, while upregulating that of E-cadherin and p21. The Notch inhibitor DAPT reduced the biological effects of KIAA0247 knockdown, suggesting that KIAA0247 decreased the carcinogenic activity of NSCLC cells through downregulation of Notch signaling. Our results indicate that KIAA0247 inhibits NSCLC progression by reducing the metastatic potential of cancer cells through downregulation of the Notch pathway, which may underlie the association of KIAA0247 expression with favorable clinicopathological characteristics of NSCLC patients. These findings suggest that KIAA0247 is a candidate prognostic biomarker and potential therapeutic target in NSCLC.

Citing Articles

GRWD1 Over-Expression Promotes Gastric Cancer Progression by Activating Notch Signaling Pathway via Up-Regulation of ADAM17.

Ding H, Feng Z, Hu K Dig Dis Sci. 2024; 69(3):821-834.

PMID: 38172445 DOI: 10.1007/s10620-023-08208-5.

Global research hotspots and trends of the Notch signaling pathway in the field of cancer: a bibliometric study.

Lei K, Wang X, Liu Y, Sun T, Xie W Am J Transl Res. 2022; 14(7):4918-4930.

PMID: 35958476 PMC: 9360898.

Deletion of -DMR Enhances Migration and Invasion of MLTC-1 Depending on the CTCF Binding Sites.

Han X, He H, Shao L, Cui S, Yu H, Zhang X Int J Mol Sci. 2022; 23(15).

PMID: 35955961 PMC: 9369160. DOI: 10.3390/ijms23158828.

5mC and H3K9me3 of TRAF3IP2 promoter region accelerates the progression of translocation renal cell carcinoma.

Yang L, Chen Y, Liu N, Lu Y, Li X, Ma W Biomark Res. 2022; 10(1):54.

PMID: 35897085 PMC: 9331078. DOI: 10.1186/s40364-022-00402-3.

TGF-β-MTA1-SMAD7-SMAD3-SOX4-EZH2 Signaling Axis Promotes Viability, Migration, Invasion and EMT of Hepatocellular Carcinoma Cells.

Zhang K, Fang T, Shao Y, Wu Y Cancer Manag Res. 2021; 13:7087-7099.

PMID: 34531686 PMC: 8439444. DOI: 10.2147/CMAR.S297765.

References

Vandooren J, Van den Steen P, Opdenakker G . Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 (MMP-9): the next decade. Crit Rev Biochem Mol Biol. 2013; 48(3):222-72. DOI: 10.3109/10409238.2013.770819. View

Niessen K, Fu Y, Chang L, Hoodless P, McFadden D, Karsan A . Slug is a direct Notch target required for initiation of cardiac cushion cellularization. J Cell Biol. 2008; 182(2):315-25. PMC: 2483533. DOI: 10.1083/jcb.200710067. View

Zheng H, Kang Y . Multilayer control of the EMT master regulators. Oncogene. 2013; 33(14):1755-63. DOI: 10.1038/onc.2013.128. View

Lanczky A, Nagy A, Bottai G, Munkacsy G, Szabo A, Santarpia L . miRpower: a web-tool to validate survival-associated miRNAs utilizing expression data from 2178 breast cancer patients. Breast Cancer Res Treat. 2016; 160(3):439-446. DOI: 10.1007/s10549-016-4013-7. View

Grana X, Reddy E . Cell cycle control in mammalian cells: role of cyclins, cyclin dependent kinases (CDKs), growth suppressor genes and cyclin-dependent kinase inhibitors (CKIs). Oncogene. 1995; 11(2):211-9. View

Miele L . Notch signaling. Clin Cancer Res. 2006; 12(4):1074-9. DOI: 10.1158/1078-0432.CCR-05-2570. View

Janciauskiene S, Bals R, Koczulla R, Vogelmeier C, Kohnlein T, Welte T . The discovery of α1-antitrypsin and its role in health and disease. Respir Med. 2011; 105(8):1129-39. DOI: 10.1016/j.rmed.2011.02.002. View

Khanna P, Blais N, Gaudreau P, Corrales-Rodriguez L . Immunotherapy Comes of Age in Lung Cancer. Clin Lung Cancer. 2016; 18(1):13-22. DOI: 10.1016/j.cllc.2016.06.006. View

Torre L, Bray F, Siegel R, Ferlay J, Lortet-Tieulent J, Jemal A . Global cancer statistics, 2012. CA Cancer J Clin. 2015; 65(2):87-108. DOI: 10.3322/caac.21262. View

10.

Bertoli C, Skotheim J, de Bruin R . Control of cell cycle transcription during G1 and S phases. Nat Rev Mol Cell Biol. 2013; 14(8):518-28. PMC: 4569015. DOI: 10.1038/nrm3629. View

11.

Wang Z, Li Y, Kong D, Sarkar F . The role of Notch signaling pathway in epithelial-mesenchymal transition (EMT) during development and tumor aggressiveness. Curr Drug Targets. 2010; 11(6):745-51. PMC: 3084452. DOI: 10.2174/138945010791170860. View

12.

Hanahan D, Weinberg R . Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. DOI: 10.1016/j.cell.2011.02.013. View

13.

Hilakivi-Clarke L, Wang C, Kalil M, Riggins R, Pestell R . Nutritional modulation of the cell cycle and breast cancer. Endocr Relat Cancer. 2004; 11(4):603-22. DOI: 10.1677/erc.1.00665. View

14.

Polato F, Rusconi P, Zangrossi S, Morelli F, Boeri M, Musi A . DRAGO (KIAA0247), a new DNA damage-responsive, p53-inducible gene that cooperates with p53 as oncosuppressor. [Corrected]. J Natl Cancer Inst. 2014; 106(4):dju053. PMC: 3988459. DOI: 10.1093/jnci/dju053. View

15.

Yuan X, Wu H, Han N, Xu H, Chu Q, Yu S . Notch signaling and EMT in non-small cell lung cancer: biological significance and therapeutic application. J Hematol Oncol. 2014; 7:87. PMC: 4267749. DOI: 10.1186/s13045-014-0087-z. View

16.

Huang C, Yang S, Huang S, Lin C, Chien C, Chen Y . A predicted protein, KIAA0247, is a cell cycle modulator in colorectal cancer cells under 5-FU treatment. J Transl Med. 2011; 9:82. PMC: 3126726. DOI: 10.1186/1479-5876-9-82. View

17.

Allen T, Rodriguez E, Jones K, Bishop J . Activated Notch1 induces lung adenomas in mice and cooperates with Myc in the generation of lung adenocarcinoma. Cancer Res. 2011; 71(18):6010-8. PMC: 3174331. DOI: 10.1158/0008-5472.CAN-11-0595. View

18.

Schiller J, Harrington D, Belani C, Langer C, Sandler A, Krook J . Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002; 346(2):92-8. DOI: 10.1056/NEJMoa011954. View

19.

Gyorffy B, Surowiak P, Budczies J, Lanczky A . Online survival analysis software to assess the prognostic value of biomarkers using transcriptomic data in non-small-cell lung cancer. PLoS One. 2013; 8(12):e82241. PMC: 3867325. DOI: 10.1371/journal.pone.0082241. View

20.

Andersson E, Lendahl U . Therapeutic modulation of Notch signalling--are we there yet?. Nat Rev Drug Discov. 2014; 13(5):357-78. DOI: 10.1038/nrd4252. View